###begin article-title 0
A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme
###end article-title 0
###begin p 1
###xml 147 154 143 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
Many B cell cancers are characterized in part by the dysregulation of the NF-kappaB signaling pathway. A new study identifies somatic mutations in TNFAIP3, the gene encoding the NF-kappaB inhibitor A20, in Hodgkin lymphomas and primary mediastinal lymphomas. These data reveal the role of A20 as a tumor suppressor protein.
###end p 1
###begin p 2
###xml 428 429 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 628 629 616 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 773 774 757 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">3</xref>
###xml 785 788 769 772 <related-article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" related-article-type="article-reference" vol="206" page="981" id="d32e96" xlink:href="19380639" ext-link-type="pubmed">981</related-article>
###xml 852 859 836 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
###xml 930 931 914 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 1057 1064 1041 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
###xml 1142 1149 1126 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
###xml 1195 1196 1179 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 1198 1199 1182 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 906 911 <span type="species:ncbi:9606">human</span>
Lymphomas are the fifth most common of human malignancies; the chance of developing lymphoma during one's lifetime is approximately2%. The vast majority of lymphomas are B cell lineage derived and can be characterized as Hodgkin or non-Hodgkin lymphomas. Both classes can be further subtyped based upon their biological properties, including differentiation stage, clinical pathology, and the response to therapeutic treatment (1). Many important clues to lymphoma pathogeneses have come from cytogenetic and genetic analyses of somatic mutations (e.g., translocations and gene deletions), as well as gene expression profiling (2). Mutations in NF-kappaB and JAK/STAT signaling proteins cause defects in B cell survival and proliferation and contribute to lymphomagenesis (3). On page 981 of this issue, Schmitz et al. examine whether mutations in the TNFAIP3 gene contribute to cellular transformation in human B cell lymphomas (4). Their data show that a large number of Hodgkin lymphomas and primary mediastinal lymphomas contain bi-allelic mutations of TNFAIP3 that result in loss of the A20 protein. Other recent studies have also found TNFAIP3 mutations in marginal zone B cell lymphomas (5, 6). These and future studies of ubiquitin modifiers may reveal new directions for the discovery of anticancer therapies.
###end p 2
###begin title 3
A20 keeps the peace
###end title 3
###begin p 4
###xml 109 110 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 219 222 215 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 321 322 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 556 557 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 672 673 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 675 677 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 766 769 758 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 775 778 767 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 874 875 866 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 1066 1068 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 210 214 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 428 432 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 452 456 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 779 783 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 935 939 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 994 998 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
A20 was first identified in 1990 as a TNF-induced molecule that restricts TNF-triggered NF-kappaB signaling (7). Its widespread expression and potent antiinflammatory functions were unveiled when A20-deficient mice (A20-/-) were found to exhibit severe spontaneous multiorgan inflammation, cachexia, and premature death (8). Epistasis experiments revealed that genetic deletion of TNF or TNF receptor 1 (TNFR1) in A20-deficient mice did not rescue the mice from premature death, demonstrating that A20 regulates proinflammatory signals in addition to TNF (9). We now know that A20 also restricts NF-kappaB signaling in response to stimulation of the TLR and NOD pathways (9, 10). A20 regulates innate immune homeostasis independently of adaptive immune cells, as A20-/- RAG-1-/- mice lacking mature T and B cells develop severe spontaneous inflammation and perinatal death (8). The defects caused by A20 deficiency were ameliorated in mice that also lacked the TLR adaptor protein MyD88 and in mice treated with antibiotics to deplete commensal intestinal bacteria (11). These results highlight the potentially proinflammatory nature of homeostatic MyD88-dependent signals, as well as A20's critical role in restricting these signals and maintaining immune homeostasis.
###end p 4
###begin title 5
The mechanics of A20 action
###end title 5
###begin p 6
###xml 729 731 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 877 878 869 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 880 882 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 1038 1040 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
The biochemical mechanisms by which A20 restricts NF-kappaB signaling are unique and complex. The A20 protein contains an ovarian tumor (OTU) domain at the N terminus and seven zinc finger (ZF) domains at the C terminus. The OTU domain functions as a deubiquitinating (DUB) enzyme to remove activating lysine-63 (K63)-linked polyubiquitin chains from receptor-interacting protein (RIP), an essential mediator of the proximal TNFR1 signaling complex. The A20 ZF domain functions as an E3 ubiquitin ligase, adding K48-linked polyubiquitin chains to RIP1 and targeting the protein for proteasomal degradation. Hence, A20 appears to be a dual function enzyme that adds and subtracts ubiquitin moieties to deactivate and degrade RIP (12). In addition to regulating TNF-induced RIP ubiquitylation, A20 restricts TLR-induced NF-kappaB signals by deubiquitylating the E3 ligase TRAF6 (9, 11). A20 also dampens NOD1- and NOD2-induced NF-kappaB signals by deubiquitylating RIP2, possibly preventing it from recruiting IKK to the signaling complex (10). Hence, like other DUBs and E3 ligases, A20 regulates the ubiquitylation of multiple protein targets.
###end p 6
###begin p 7
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
A20 also binds to the E3 ligases TRAF1, TRAF2, TRAF6, Itch, and RNF11, as well as to the adaptor protein TXBP1 and the ubiquitin sensor ABIN-1 (13-17). These proteins collaborate with A20 to regulate NF-kappaB and MAP kinase signaling cascades and TNF-induced cell death. How this ubiquitin-dependent, multiprotein complex functions, how it targets specific signaling cascades, and whether distinct subsets of this complex preferentially regulate different signaling proteins are among the questions that remain to be answered.
###end p 7
###begin p 8
###xml 47 48 47 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 349 350 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
A20 also inhibits programmed cell death (PCD) (8, 18). Increased susceptibility to PCD in A20-deficient cells is not caused by deficiencies in the expression of NF-kappaB-induced survival proteins, as these cells have exaggerated NF-kappaB signaling and normal expression of NF-kappaB survival proteins, yet are more susceptible to TNF-induced PCD (8). Because limiting the lifespan of activated immune cells helps restrain inflammatory responses, the antiinflammatory and antiapoptotic functions of A20 impart dichotomous regulatory influences on immune homeostasis.
###end p 8
###begin title 9
A20 in lymphocytes
###end title 9
###begin p 10
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 450 452 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
Although most studies investigating the function of A20 have focused on innate immune signals, A20 is constitutively expressed and can be further induced in both T and B cells (7, 8, 19). However, the protein's function in lymphocytes is poorly understood. In T cells, the mucosal-associated lymphoid tumor-associated (MALT1) protein cleaves A20 during TCR activation, which is one mechanism by which MALT1 promotes TCR-induced NF-kappaB activation (20). BCR stimulation of B lymphoma cell lines also leads to A20 cleavage. However, the physiological role of A20 and its cleavage in T and B cells is unclear. Mature B cells are regulated by NF-kappaB signals triggered by the BCR, BAFF, and CD40. Because these signaling cascades may share some of the same ubiquitin-dependent proximate signaling molecules used by TNF and TLR ligands (e.g., TRAF2, TRAF6), it is possible that A20 may also regulate B cell homeostasis and activation.
###end p 10
###begin title 11
A20's cancer connection
###end title 11
###begin p 12
###xml 178 179 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">3</xref>
###xml 415 422 407 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
###xml 464 465 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 516 521 <span type="species:ncbi:9606">human</span>
A20-deficient cells exhibit prolonged NF-kappaB signaling in response to a variety of innate immune ligands, and chronic NF-kappaB activation has been associated with lymphomas (3). Genetic analyses have identified deletions in chromosome 6q that are associated with Hodgkin lymphoma and other subtypes of B cell lymphomas (e.g., marginal zone lymphomas, MALT lymphomas, and diffuse large B cell lymphomas). As the TNFAIP3 gene is located at 6q23, Schmitz et al. (4) proposed that A20 might be pathogenetic in these human cancers. The authors focused their molecular analysis on primary mediastinal B cell lymphomas (PMBLs) and classical Hodgkin lymphoma (cHL), as the transcriptional profiles of these tumors are similar.
###end p 12
###begin p 13
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
###xml 358 363 <span type="species:ncbi:9606">human</span>
Remarkably, they found that bi-allelic somatic mutations in TNFAIP3 were found in 16/36 cHLs and 5/14 PMBLs. Reconstitution of A20 expression induced cell death in A20 mutant lymphoma cell lines, but not in A20-sufficient lymphoma cells. These findings provide direct evidence that A20 is a tumor suppressor gene that is mutated with high frequency in these human lymphomas.
###end p 13
###begin p 14
###xml 471 473 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 475 477 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
Schmitz el al. also make the intriguing observation that A20 mutations are found in 14/20 (70%) EBV-negative cHL compared with only 2/16 (12.5%) EBV-positive lymphomas, suggesting that EBV-dependent transformation perturbs B cell signaling in a fashion similar to A20 deletion. Indeed, earlier studies suggested that the EBV latent membrane protein 1 may mimic CD40 signaling by interacting with TRAFs, and perhaps A20, thereby inducing constitutive NF-kappaB signaling (21, 22). Although the precise biochemical relationships between EBV proteins and A20 are unclear, the genetic epistasis unveiled by Schmitz et al. may provide intriguing clues about B cell lymphomagenesis.
###end p 14
###begin p 15
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
Most of the TNFAIP3 mutations found in Hodgkin and mediastinal lymphomas were nonsense or frameshift mutations that prevented production of full-length A20 protein (4). Combined with the observation that both alleles were mutated in the tumor samples, the common pathogenetic mechanism of A20 in lymphoma development is likely a loss of protein function. Mutations were found throughout the coding sequence, and some mutations had the potential to encode partial proteins. As partial A20 proteins containing only the N-terminal OTU domain have been shown to retain deubiquitinating activity (9), the E3 ligase activity of A20 may be critical for its tumor suppressor function. It is also intriguing that six of the seven replacement mutations observed in both cHL and PMBL were clustered in the terminal zinc finger domains ZF6 and ZF7, which are thought to be largely dispensable for A20's E3 ligase activity (12). This suggests that subtle reductions in E3 ligase activity that may result from these mutations can be tumorigenic. Alternatively, previously unappreciated functions of A20 may be harbored in these domains.
###end p 15
###begin title 16
Autoimmunity-cancer link?
###end title 16
###begin p 17
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 171 178 171 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 650 657 650 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
###xml 869 876 869 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
###xml 1271 1272 1271 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 1286 1287 1286 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 1289 1290 1289 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 126 132 <span type="species:ncbi:9606">humans</span>
###xml 462 466 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 569 574 <span type="species:ncbi:9606">human</span>
###xml 905 913 <span type="species:ncbi:9606">patients</span>
###xml 1187 1192 <span type="species:ncbi:9606">human</span>
###xml 1382 1387 <span type="species:ncbi:9606">human</span>
###xml 1388 1396 <span type="species:ncbi:9606">patients</span>
Several chronic autoimmune diseases are associated with increased risk of developing lymphoma (23). Recent genetic studies in humans revealed several polymorphisms in the TNFAIP3 gene region as risk alleles for the development of systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriasis, and celiac disease (24-29). While only one missense coding allele has been identified thus far (in SLE), the well-established antiinflammatory functions of A20 in mice suggest that hypomorphic function or expression of A20 may contribute to the pathophysiology of these human conditions (24). Collectively, these findings suggest that subtle germline TNFAIP3 hypomorphisms may predispose individuals to chronic autoimmune diseases, whereas gross A20 deficiencies occurring somatically may contribute to lymphoma. In this context, it will be revealing to further analyze TNFAIP3 polymorphisms in autoimmune patients and determine whether there is an association between certain polymorphisms and lymphoma risk. Considered from another perspective, the severe pathogenetic consequences of A20 deficiency may mean that deletional germline mutations of A20 are unlikely to be detected in the human population. These studies along with the results presented by Schmitz et al. (4) and others (5, 6) suggest that A20 may be a prevalent suppressor of both autoimmune disease and lymphoma in human patients, thereby providing a critical molecular link between chronic inflammation and cancer.
###end p 17
###begin title 18
Questions for the future
###end title 18
###begin p 19
###xml 160 167 160 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
###xml 218 222 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 378 382 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 673 677 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
As in most malignancies, the generation of lymphomas is likely to involve somatic mutations of multiple genes. Identifying oncogenic events that cooperate with TNFAIP3 deletions in lymphomagenesis can now be tested in mice bearing mutations in known oncogenes or tumor suppressor genes. In this context, the rampant inflammation and markedly shortened lifespan of A20-deficient mice have largely precluded efforts to monitor these animals for spontaneous tumor development. Lineage-specific deletions of A20 may greatly facilitate these studies. In this regard, it will be particularly interesting to determine how A20 intrinsically regulates B cell functions by analyzing mice lacking A20 specifically in B cells.
###end p 19
###begin p 20
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
Many questions also remain unresolved regarding the role of A20 in promoting and/or blocking cell death. Although expression of A20 triggered PCD in A20 mutant lymphomas, A20 also acts as a survival protein, as it protects most cells from TNF-induced PCD (7, 8). This feature sets A20 apart from most other known tumor suppressors (e.g., p53), which are proapoptotic, antiproliferative, or both. This dichotomy of A20 function may provide clues regarding secondary mutations that may collaborate with A20 mutations to promote tumorigenesis. It is also important to note that A20 may regulate JNK signaling pathways via its interactions with TRAF2 (13, 14). Hence, regulation of the NF-kappaB pathway may not be A20's sole function in tumorigenesis.
###end p 20
###begin p 21
###xml 34 41 34 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFAIP3</italic>
The remarkably high prevalence of TNFAIP3 mutations in these lymphomas suggests that A20 is a biomedically important tumor suppressor. In addition, A20 and NF-kappaB are expressed in virtually all cell types; thus, A20 deletions may be involved in the pathogenesis of other lymphomas and/or other malignancies. The continuing identification of proteins that interact with A20 may also reveal other candidate tumor suppressors.
###end p 21
###begin p 22
Finally, akin to the dysregulation of phosphorylation-dependent signaling events in cancer pathogenesis, the identification of ubiquitin-dependent events that contribute to transformation opens up new opportunities for tumor classifications and novel therapeutics. Dissecting the precise biochemical mechanisms of A20 function, e.g., how proximate signaling molecules are ubiquitinated, how ubiquitin-dependent sensors and enzymes interact, and what structural motifs determine ubiquitin sensing, may lead to molecular insights that spawn small molecule inhibitors of ubiquitin-dependent protooncogenic signals.
###end p 22
###begin article-title 23
Classification of lymphoid neoplasms: the microscope as a tool for disease discovery.
###end article-title 23
###begin article-title 24
A library of gene expression signatures to illuminate normal and pathological lymphoid biology.
###end article-title 24
###begin article-title 25
The biology of Hodgkin's lymphoma.
###end article-title 25
###begin article-title 26
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin's lymphoma and primary mediastinal B cell lymphoma.
###end article-title 26
###begin article-title 27
TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma.
###end article-title 27
###begin article-title 28
The NF-kB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas.
###end article-title 28
###begin article-title 29
The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein.
###end article-title 29
###begin article-title 30
###xml 84 88 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice.
###end article-title 30
###begin article-title 31
The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses.
###end article-title 31
###begin article-title 32
The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain-containing 2 triggered signals.
###end article-title 32
###begin article-title 33
Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20.
###end article-title 33
###begin article-title 34
Deubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling.
###end article-title 34
###begin article-title 35
The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation.
###end article-title 35
###begin article-title 36
The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN.
###end article-title 36
###begin article-title 37
The zinc finger protein A20 interacts with a novel anti-apoptotic protein which is cleaved by specific caspases.
###end article-title 37
###begin article-title 38
The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20.
###end article-title 38
###begin article-title 39
The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling.
###end article-title 39
###begin article-title 40
The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity.
###end article-title 40
###begin article-title 41
Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis.
###end article-title 41
###begin article-title 42
T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20.
###end article-title 42
###begin article-title 43
###xml 27 45 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses.
###end article-title 43
###begin article-title 44
###xml 35 53 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The A20 protein interacts with the Epstein-Barr virus latent membrane protein 1 (LMP1) and alters the LMP1/TRAF1/TRADD complex.
###end article-title 44
###begin article-title 45
Autoimmunity and lymphomagenesis.
###end article-title 45
###begin article-title 46
Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus.
###end article-title 46
###begin article-title 47
Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus.
###end article-title 47
###begin article-title 48
Two independent alleles at 6q23 associated with risk of rheumatoid arthritis.
###end article-title 48
###begin article-title 49
Rheumatoid arthritis association at 6q23.
###end article-title 49
###begin article-title 50
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways.
###end article-title 50
###begin article-title 51
Coeliac disease associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signaling.
###end article-title 51

